Youinou P - Search Results

1

Is the c-Cbl proto-oncogene involved in chronic lymphocytic leukemia?

Mankaï A, Eveillard JR, Buhé V, Le Ster K, Loisel S, Ghedira I, Youinou P, Berthou C, Bordron A. Mankaï A, et al. Among authors: youinou p. Ann N Y Acad Sci. 2007 Jun;1107:193-205. doi: 10.1196/annals.1381.021. Ann N Y Acad Sci. 2007. PMID: 17804547

2

Purine-rich box-1-mediated reduced expression of CD20 alters rituximab-induced lysis of chronic lymphocytic leukemia B cells.

Mankaï A, Bordron A, Renaudineau Y, Martins-Carvalho C, Takahashi S, Ghedira I, Berthou C, Youinou P. Mankaï A, et al. Among authors: youinou p. Cancer Res. 2008 Sep 15;68(18):7512-9. doi: 10.1158/0008-5472.CAN-07-6446. Cancer Res. 2008. PMID: 18794139

3

Improvement of rituximab efficiency in chronic lymphocytic leukemia by CpG-mediated upregulation of CD20 expression independently of PU.1.

Mankaï A, Buhé V, Hammadi M, Youinou P, Ghedira I, Berthou C, Bordron A. Mankaï A, et al. Among authors: youinou p. Ann N Y Acad Sci. 2009 Sep;1173:721-8. doi: 10.1111/j.1749-6632.2009.04614.x. Ann N Y Acad Sci. 2009. PMID: 19758221

4

CpG ODN enhances the efficacy of rituximab in non-Hodgkin lymphoma.

Buhé V, Guerrier T, Youinou P, Berthou C, Loisel S. Buhé V, et al. Among authors: youinou p. Ann N Y Acad Sci. 2009 Sep;1173:858-64. doi: 10.1111/j.1749-6632.2009.04615.x. Ann N Y Acad Sci. 2009. PMID: 19758238

5

CD5 links humoral autoimmunity with B-cell chronic lymphocytic leukemia.

Mankai A, Bordron A, Renaudineau Y, Berthou C, Ghedira I, Youinou P. Mankai A, et al. Among authors: youinou p. Expert Rev Clin Immunol. 2007 May;3(3):333-41. doi: 10.1586/1744666X.3.3.333. Expert Rev Clin Immunol. 2007. PMID: 20477677

6

Therapeutic activity of two xanthones in a xenograft murine model of human chronic lymphocytic leukemia.

Loisel S, Le Ster K, Meyer M, Berthou C, Youinou P, Kolb JP, Billard C. Loisel S, et al. Among authors: youinou p. J Hematol Oncol. 2010 Dec 7;3:49. doi: 10.1186/1756-8722-3-49. J Hematol Oncol. 2010. PMID: 21138552 Free PMC article.

7

B cell response to surface IgM cross-linking identifies different prognostic groups of B-chronic lymphocytic leukemia patients.

Nédellec S, Renaudineau Y, Bordron A, Berthou C, Porakishvili N, Lydyard PM, Pers JO, Youinou P. Nédellec S, et al. Among authors: youinou p. J Immunol. 2005 Mar 15;174(6):3749-56. doi: 10.4049/jimmunol.174.6.3749. J Immunol. 2005. PMID: 15749915

8

Establishment of a novel human B-CLL-like xenograft model in nude mouse.

Loisel S, Ster KL, Quintin-Roue I, Pers JO, Bordron A, Youinou P, Berthou C. Loisel S, et al. Among authors: youinou p. Leuk Res. 2005 Nov;29(11):1347-52. doi: 10.1016/j.leukres.2005.04.017. Leuk Res. 2005. PMID: 15896841

9

B lymphocytes are required for development and treatment of autoimmune diseases.

Youinou P, Jamin C, Pers JO, Berthou C, Saraux A, Renaudineau Y. Youinou P, et al. Ann N Y Acad Sci. 2005 Jun;1050:19-33. doi: 10.1196/annals.1313.003. Ann N Y Acad Sci. 2005. PMID: 16014517 Review.

10

CD5 promotes IL-10 production in chronic lymphocytic leukemia B cells through STAT3 and NFAT2 activation.

Garaud S, Morva A, Lemoine S, Hillion S, Bordron A, Pers JO, Berthou C, Mageed RA, Renaudineau Y, Youinou P. Garaud S, et al. Among authors: youinou p. J Immunol. 2011 Apr 15;186(8):4835-44. doi: 10.4049/jimmunol.1003050. Epub 2011 Mar 11. J Immunol. 2011. PMID: 21398617 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

609 results

Search Page

Filters